CMR Surgical: Galaxy Care Becomes First Hospital in the World to Acquire the Versius Surgical Robotic System
CMR Surgical Ltd today announced that Galaxy Care Hospital in Pune, India, has become the first hospital in the world to procure Versius ® , a next-generation surgical robotic system. A range of surgical procedures have already been conducted using Versius® at the world-renowned centre for laparoscopy, including transthoracic, hysterectomies and myomectomies, under the leadership of Dr. Shailesh Puntambekar.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191015005940/en/
Galaxy Care is a well-established centre of excellence for laparoscopic surgery and the introduction of Versius ® will support the hospital to bring robotic-assisted laparoscopic surgery to more people. Dr Shailesh Puntambekar, Consultant Oncologist, Surgeon and Medical Director of Galaxy Care will lead the team using Versius ® . He is an international pioneer in surgery and renowned for his advanced laparoscopic skills. In addition to this, he is responsible for training laparoscopy to surgeons from all over the world, helping to bring the benefits of minimal access surgery to patients globally.
Dr Puntambekar has led the way in bringing surgical robotics to India, having performed robotic-assisted surgery in India for over a decade and will be responsible for the introduction of Versius ® to Galaxy Care. Versius ® as a next-generation surgical robotic system with its small form factor, versatility and portability has been designed to support surgeons to deliver the benefits of minimal access surgery to patients around the world.
“As an experienced surgeon in robotic assisted surgery I think that there is significant potential for Versius ® to further increase access to laparoscopic surgery for my patients, so it was a natural choice to acquire this system. Versius ® , as a small and cost-effective system is well suited for meeting the high surgical demand in India. We are excited to bring the next-generation surgical robot to India.” said Dr. Shailesh Puntambekar, Medical Director at Galaxy Care Hospital, Pune, India.
“Galaxy Care has become our first customer to acquire and use Versius ® and this is an important milestone in bringing the benefits of minimal access surgery to all. We are pleased to be working with a centre that has some of the best surgeons in the world, meeting a high surgical demand. It is important that we bring Versius ® to market responsibly and we are delighted to be working closely with Galaxy Care on the introduction of Versius ® in the hospital”, said Mark Slack, Chief Medical Officer, CMR Surgical.
The commercial introduction of Versius ® also marks the launch of the world’s first clinical registry for a surgical robotic system. The registry is part of CMR Surgical’s commitment to post-market surveillance as part of the IDEAL framework and a responsible introduction of a medical device. The clinical registry managed by CMR Surgical, working in partnership with customers is recording and monitoring the patient outcomes of all procedures conducted using the Versius ® Surgical Robotic System in order to ensure patient safety. Outcome measures being recorded include: operative time, length of stay, return to hospital within 30 days, and return to operating room within 24 hours.
In addition to the first global commercial deal taking place in India, the Versius® Surgical Robotic System is expected to be introduced in hospitals across Europe later in 2019.
---ENDS---
About the Galaxy Care Hospital, Pune, India
Galaxy Care Hospital located in Pune, India is a specialist centre in laparoscopic and Robotic cancer surgeries. It has the first and only robotic theatre in western and southern India. The hospital is led by Medical Director Dr. Shailesh Puntambekar who has performed a number of internationally acclaimed procedures including India’s first successful womb transplant as well as pioneering laparoscopic radical hysterectomy for early stage cervical cancer, known globally as the Pune technique. Galaxy Care is now associated with the Care Group of Hospitals, with a number of hospitals across India.
About the Clinical Registry
The clinical registry established by CMR Surgical, working in partnership with customers will support post-market surveillance for the Versius ® Surgical Robotic System. The clinical registry will be collecting the following clinical data on procedures conducted using Versius ® : patient demographics, surgical history, date of diagnosis, planned procedure, operative time, estimated blood loss, return to operating theatre within 24 hours, length of stay, return to hospital within 30 days, mortality at 90 days, any complications that may have occurred. All data is anonymised.
About the Versius® Surgical Robotic System
Versius® resets expectations of robotic surgery by providing a versatile system that is portable, transportable and affordable. This is made possible because of its elegant form factor, modular design and individually cart-mounted arms. Versius® can move between operating rooms and even hospitals/clinics and gives the surgical team excellent access to the patient at all times.
Biomimicking the human arm, Versius® allows surgeons the freedom of port placement, but with the benefits of small fully-wristed instruments. With 3D HD vision, easy-to adopt instrument control and a choice of ergonomic working positions, the new open surgeon console has the potential to reduce stress and fatigue and extend the careers of surgeons.
About CMR Surgical Limited
CMR Surgical is a British private limited company developing the next-generation universal robotic system, Versius®, for minimal access surgery. The company received the European CE Mark in March 2019 for the Versius® Surgical Robotic System.
The vision behind CMR Surgical is to make minimal access surgery universally accessible and affordable, transforming the existing market for surgical robotics while also addressing the six million people who still undergo open surgery each year.
Global annual revenues for robot-assisted minimal access surgery are presently approximately $4 billion and are anticipated to reach $20 billion by 2025.
CMR Surgical, formed in 2014, has its headquarters in Cambridge, United Kingdom and is backed by an international shareholder base of specialist and generalist investors.
The Company achieved the registration of its Quality Management System to ISO 13485:2016 by Underwriters Laboratories LLC® (UL), and the status as a UL Registered Firm, in September 2015.
For further information, please visit www.cmrsurgical.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191015005940/en/
Contact information
CMR Surgical
Patrick Pordage/ Sarah Ghabina
patrick.pordage@cmrsurgical.com/ sarah.ghabina@cmrsurgical.com
+44 (0)7864 922341 /+44 (0)7749 432373
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Visa Launches Stablecoin Settlement in the United States, Marking a Breakthrough for Stablecoin Integration16.12.2025 14:00:00 EET | Press release
Visa Inc. (V) today announced the launch of USDC settlement in the United States, marking a major milestone in the company’s stablecoin settlement pilot program and strategy to modernize its settlement layer underpinning global commerce. For the first time, U.S. issuer and acquirer partners can settle with Visa in Circle’s USDC, a fully reserved, dollar-denominated stablecoin. With USDC settlement, issuers can benefit from faster funds movement over blockchains, seven‑day availability and enhanced operational resilience across weekends and holidays - without any change to the consumer card experience. Initial banking participants include Cross River Bank and Lead Bank, which have started settling with Visa in USDC over the Solana blockchain. Broader availability in the U.S. is planned through 2026. Additionally, Visa is a design partner for Arc, a new Layer 1 blockchain developed by Circle (currently in public testnet). Arc’s purpose-built design offers the performance and scalability
Dompé Doses First Patients in Europe and US in Phase 3 Study of Isocyclosporin for Atopic Keratoconjunctivitis16.12.2025 14:00:00 EET | Press release
Dompé, a leading biopharmaceutical company with operations in Italy and the U.S., announced the first patients have been enrolled in a Phase 3 study of Isocyclosporin for the treatment of atopic keratoconjunctivitis (AKC). Isocyclosporin is a dual inhibitor of transient receptor potential (TRP) cation channel, mucolipin subfamily, member 2 (TRPML2) and calcineurin, key regulators of immune and inflammatory response in chronic inflammatory eye diseases. The Phase 3 trial is a multicenter, randomized, double-masked study comparing isocyclosporin against vehicle control in improving ocular signs and symptoms after six weeks of treatment. “This milestone underscores Dompé’s commitment to groundbreaking science with the potential for life-changing patient impact,” said Marcello Allegretti, Chief Scientific Officer at Dompé. “The dual mechanism of isocyclosporin has the potential to redefine treatment and quality of life for patients living with poorly managed AKC. It also marks an important
Volante Technologies Customers Successfully Navigate Critical Regulatory Deadlines for EU SEPA Instant and Global SWIFT Cross-Border Payments16.12.2025 11:00:00 EET | Press release
Volante Technologies, the global leader in Payments as a Service (PaaS), today announced it has successfully upgraded its clients to meet the latest SEPA Instant Payments Regulation (IPR) and SWIFT SRG 2025 mandate, which came into effect October 9th and November 22nd, 2025, respectively. This announcement follows the major FedISO upgrade in July, which shifted trillions of dollars in payments to the new ISO 20022 messaging format. SEPA IPR is a significant European milestone, requiring payments to be made within 10 seconds and at any time of day, throughout the year. Adoption was mandatory and Eurozone banks were compelled to meet strict deadlines, with January 9th, 2025 the deadline for receiving incoming instant payments and October 9th the deadline for sending outgoing instant payments. The latest deadline impacted more than 700 banks across Europe, with non-compliance penalties reaching at least 10% of annual net turnover. SWIFT SRG 2025 is another seismic update, representing the
TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth16.12.2025 10:05:00 EET | Press release
TreeFrog Therapeutics, a French biotech focused on bringing regenerative medicine to millions through their proprietary cell technology, C-Stem™ is delighted to announce the appointment of skilled biotech leader, Mark Rothera, as Chief Executive Officer and Board member. He succeeds Frédéric Desdouits, who is stepping down after five years in the role. In the new leadership configuration, co-founders Kévin Alessandri and Maxime Feyeux will transition from daily operations to focus on their roles on the Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215145193/en/ Mark Rothera, CEO TreeFrog Therapeutics Elsy Boglioli, Chair of the Board of TreeFrog Therapeutics, commented “On behalf of the Board, we are delighted to welcome Mark to TreeFrog. His 30+ years of biopharma leadership, including most recently, three biotech CEO roles in gene therapy and biologics, will be invaluable as we advance our Parkinson’s and liver
RoslinCT and Ayrmid Ltd. Announce Expansion of Strategic Partnership to Manufacture Omisirge ® (omidubicel-onlv) for Second FDA-Approved Indication in Severe Aplastic Anemia (SAA)16.12.2025 10:00:00 EET | Press release
Ayrmid Ltd., the parent company of Gamida Cell Inc., a pioneering cell therapy company transforming cells into powerful therapeutics, and RoslinCT, a global leader in cell and gene therapy contract development and manufacturing, today announced the expansion of their strategic partnership to include the execution of a commercial supply agreement to support production of Omisirge® (omidubicel-onlv). Following positive clinical trial results, Omisirge® has received FDA approval for a second indication, broadening its use in the treatment of hematology patients. Under the commercial supply agreement, RoslinCT will complete technology transfer and support commercial manufacturing of Omisirge® for this additional indication at its state-of-the-art cGMP cell therapy manufacturing facility in Hopkinton, MA. “We are excited to expand our collaboration with RoslinCT to add US manufacturing as Omisirge® moves into its next phase with the recent FDA approval for patients suffering from severe apl
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom